Evaluating fatigue and molecular mechanisms in cancer patients undergoing combined chemotherapy and radiation therapy

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate cancer-related fatigue (CRF) in patients receiving standard combined chemotherapy and radiation therapy (CCRT). It will assess the relationship between molecular characteristics and CRF severity at various stages of treatment. The study will also explore the association between changes in CRF and gene expression levels, as well as circulating cytokine levels. Additionally, predictive models for CRF and chemotherapy-induced peripheral neuropathy (CIPN) severity will be developed using demographic and clinical data.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants have not received any prior treatment (i.e., cancer systemic therapies or radiation therapy) in the month except surgery or inductive Chemotherapy (CTX).
* Participants receiving \>= 15 fractions.
* Participants is male or female and is \>18 years of age on the day of signing the informed consent.
* Ability to understand a written informed consent document.
* Able and willing to complete all of the study questionnaires and provide blood and stool samples prior to, midway, and following the completion of treatment.
* Willing to have medical records reviewed for clinical information.
* Able to read, write and understand English or Spanish.

Exclusion Criteria:

* Contraindication to phlebotomy for removal of approximately 50 mL of peripheral blood within 6 week period (Institutional Review Board (IRB) limit).

Where it's running

• University of California, San Francisco
  San Francisco, California, United States Recruiting

Study contacts

• Principal investigator: Sue Yom, MD — University of California, San Francisco
• Study coordinator: Imani Dunn
• Email: Imani.Dunn@ucsf.edu
• Phone: 877-827-3222

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• High-precision detection of leftover cancer using a liquid-biopsy platform (SHERLOCK)

  This project will test whether sensitive blood and other fluid tests for circulating tumor DNA can find leftover cancer (minimal residual disease) in adults treated with curative intent for breast, lung, melanoma, gynecologic, or genitourinary cancers.

  Recruiting University Health Network, Toronto · Toronto, Ontario · NCT07524114

• Evaluating Proton Therapy for Tumors Previously Treated with Radiation

  This study is testing a new type of radiation therapy called proton therapy to see if it can help people with tumors that have already been treated with radiation, while causing less harm to healthy tissues.

  Recruiting The New York Proton Center · New York, New York · NCT05313191

• Effects of Atezolizumab on Cancer Patients with Sensitive Tumor DNA or RNA

  This study is testing if atezolizumab can help cancer patients with certain tumor types that show they might respond well to the treatment.

  Recruiting Phase 2 British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT04273061

• Blood extracellular vesicles to detect chemotherapy-related nerve damage.

  We will test whether tiny blood particles called extracellular vesicles can predict who will develop chemotherapy-induced peripheral neuropathy in adults receiving taxane, platinum, or antimitotic chemotherapy.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07558447

• Riluzole to prevent thinking and memory problems during chemotherapy

  This pilot trial tests whether riluzole can prevent thinking and memory problems in adults with cancer receiving anthracycline- or platinum-based chemotherapy.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT07447050

• Sodium thiosulfate to protect hearing during cisplatin therapy in adults with solid tumors

  This study tests Pedmark sodium thiosulfate to see if it reduces hearing loss in adults receiving standard cisplatin chemotherapy.

  Recruiting Phase 1/2 University of Arizona · Tucson, Arizona · NCT07407582

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.